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ABSTRACT
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma 
cells in the bone marrow (BM). Recently, several studies have highlighted the role 
of pathogens in either promoting or dampening malignancies of unrelated origin. 
Trypanosoma brucei is an extracellular protozoan parasite which causes sleeping 
sickness. Our group has previously demonstrated that trypanosome infection affects 
effector plasma B cells. Therefore, we hypothesized that T. brucei infection could 
have an impact on MM development. Using the immunocompetent 5T33MM model, 
we demonstrated a significant reduction in BM-plasmacytosis and M-protein levels in 
mice infected with T. brucei, resulting in an increased survival of these mice. Blocking 
IFNγ could only partially abrogate these effects, suggesting that other mechanisms 
are involved in the destruction of malignant plasma cells. We found that T. brucei 
induces intrinsic apoptosis of 5T33MM cells in vivo, and that this was associated 
with reduced endogenous unfolded protein response (UPR) activation. Interestingly, 
pharmacological inhibition of IRE1α and PERK was sufficient to induce apoptosis in 
these cells. Together, these results demonstrate that trypanosome infections can 
interfere with MM development by suppressing endogenous UPR activation and 
promoting intrinsic apoptosis.
INTRODUCTION
Recently, an increasing number of publications 
have confirmed the positive or in rare cases the negative 
relationship existing between infectious agents and 
cancer. In fact, many bacteria or viruses were shown 
to exert a malignancy enhancing role. In 2012, a study 
published in Lancet attributed 16% of cancer occurring 
in 2008 to bacteria or viruses [1]. In Africa, this rate 
more than doubled as 36% of all cancers potentially 
result from infection [2]. Haematological malignancies, 
such as multiple myeloma (MM), have become a major 
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cause of death and disability in developing countries and 
particularly in Sub-Saharan Africa, where it should start 
to slowly eclipse pathogenic diseases, such as HIV and 
malaria by 2030 [3].
MM is the 2nd most frequent hematological cancer 
after non-Hodgkin lymphomas and represents 2% of all 
cancer related deaths in the USA with a median age at 
diagnosis of 69 years [4]. Due to the accumulation of 
malignant plasma cells, typical MM related end-organ 
damage can occur, such as anemia, renal failure, osteolytic 
lesions and immunosuppression [5]. 
African Trypanosomiasis (AT) is a chronic 
human and livestock infectious disease mediated by an 
extracellular protozoan parasite, Trypanosoma. The in vivo 
mouse model of AT is characterized by the development 
of an efficient type 1 inflammatory immune response 
mainly governed by the production of IFNɣ cytokine [6]. 
However, in order to establish a chronic infection within 
its host, AT have developed numerous mechanisms of 
immune escape [7]. For example, using an in vivo mouse 
model, our laboratory has demonstrated that T. brucei 
infections are able to modulate B cell homeostasis in 
primary and secondary lymphoid organs, respectively 
BM and spleen [8], hereby abolishing the vaccine-induced 
memory response against an unrelated pathogen [9] as 
well as blocking the development of arthritis in a collagen-
induced arthritis mouse model [10].
Taken the fact that trypanosomes have adopted 
the capacity to induce a major remodeling of the host 
B cell compartment, we wished to investigate whether 
trypanosome infections could affect the outcome of 
MM. We herefore used the 5T33MM model, which is 
an immune competent model of MM, that mimics the 
human disease characteristics very closely in terms of BM 
homing, the production of M-protein (serum M-spike) and 
the development of osteolytic bone lesions [11]. 
RESULTS
In vivo effects of T. brucei infection in the 
5T33MM murine model
Our group has previously shown that T. brucei 
infection is able to alter B cell homeostasis and their 
effector functions [8-10]. Therefore, we determined if 
trypanosome infection was affecting the development 
of the 5T33MM plasma cell malignancy in the C57BL/
KalwRij mouse substrain; which is susceptible to 
hematological malignancies. In order to avoid any impact 
of the T. brucei parasite on the initial homing of the MM 
cells, 5T33MM cells were injected intravenously into 
C57BL/KalwRij mice one week prior to initiation of 
the trypanosome infection (Figure 1A). Interestingly we 
demonstrated that these mice lived significantly longer 
compared to uninfected mice administered only with 
5T33MM cells (36 days vs 22 days, Figure 1B). In this 
malignant MM model, 18 to 22 days is the typical survival 
time post-5T33MM inoculation and this early morbidity is 
associated with substantial plasmacytosis in the BM and 
M-spike in the serum [11]. Therefore it is striking to note 
that T. brucei infection of MM mice, 7 days post-5T33MM 
administration significantly reduced BM plasmacytosis by 
35% compared to uninfected 5T33MM mice twenty days 
after MM inoculation. This time point coincides with the 
moment that uninfected 5T33MM mice showed the first 
signs of morbidity (Figure 1C). This was also accompanied 
by a strong 85% reduction in serum M-spike (Figure 1D). 
These results most likely explain the extended survival of 
T. brucei infected compared to uninfected 5T33MM mice 
depicted in Figure 1B. Importantly, to date no information 
has been published on the evolution of parasitemia and 
survival of C57BL/KaLwRij mice infected with T. 
brucei. Hence, we observed that trypanosome infected 
C57BL/KaLwRij mice had a first peak of parasitemia at 
day 5-6 post-infection, which was followed by a second 
parasitemia peak at day 15 leading to morbidity due to 
uncontrolled parasitemia approximately 25 days post-
infection onwards (Figure 1E and 1F). For this reason, 
it was technically not possible to follow the impact of 
trypanosome infection on the outcome of 5T33MM 
inoculation in susceptible C57BL/KaLwRij mice, beyond 
4 weeks post infection (approximately 5 weeks post 
5T33MM inoculation). Additional data showed that tumor 
suppression started 14 days post 5T33MM inoculation (7 
days post T. brucei infection) (Figure 1G). Together, these 
results demonstrated that trypanosomiasis is significantly 
extending the survival of 5T33MM mice via the reduction 
of MM tumor load both in BM and serum. To determine 
whether the therapeutic effect on MM still persists upon 
control of infection, we treated mice receiving both MM 
and T. brucei with Berenil, which eradicates the parasites, 
one week after inoculation with T. brucei. This led to a 
median survival of 29 days which is 7 days longer than 
mice injected with MM alone but not as long as mice 
receiving both MM and T. brucei (Figure 1B). This 
indicates that the therapeutic effect does not persist upon 
parasite clearance but rather depends on the presence of 
live parasite to dampen tumoral load.
Mechanisms of T. brucei mediated apoptosis of 
5T33MM cells in vivo
Next, the mechanisms implicated in T. brucei 
mediated tumor suppression were investigated. In the 
period between day 17 and 20 after 5T33MM inoculation, 
differences in bone marrow plasmacytosis between 
uninfected and infected 5T33MM mice were most 
pronounced (Figure 1G). Therefore day 20 was chosen as 
time point to isolate MM cells. We found that the MM 
cells died by apoptosis, as shown by cleavage of caspase-3 
and PARP (Figure 2). Processing of caspase-9 but not 
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Figure 1: In vivo effects of T. brucei infection in the 5T33MM murine model. A. Schematic of the experimental set-up. B.-D.+G. 
7 days after inoculation with 5T33MM, mice were divided into 3 groups. One group was infected with T. brucei, one with T. brucei and 
Berenil, and one which served as control. B. Kaplan-Meier survival curve of 5T33MM diseased mice (n = 10/group) treated with or without 
T. brucei and Berenil. Survival of T. brucei infected mice was significantly longer compared to vehicle (p < 0,02). C.-D. Tumor load was 
evaluated by measuring plasmacytosis in the bone marrow and M-protein levels in serum of all mice when the first mouse showed signs of 
morbidity (n = 10/group). G. Plasmacytosis was counted at different time points during MM development in treated and non-treated mice, 3 
mice per time point. E.+F. naive C57BL/KaLwRij mice were infected with T. brucei. E. Parasitemia in blood was counted at different time 
points, 3 mice per time point. F. Kaplan-Meier curve of naive mice (n = 5). The bars represent mean +/- standard deviation (SD). *means 
p < 0,05, ** means p < 0,01, *** means p < 0,001. 
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of caspase-8 further demonstrated the activation of the 
intrinsic apoptotic pathways. Apoptosis induction was 
also associated with reduced MCL-1 levels, and normal 
expression of Bim and Bax. Although JNK levels were 
higher, the activated state of the kinase was unchanged 
(Figure 2). 
In order to cope with the high demand of protein 
synthesis, highly secretory cells, such as plasma cells, 
constitutively activate the unfolded protein response 
(UPR), a signaling network initiated by IRE1α, PERK 
and ATF6 that aims at maintaining ER proteostasis [12]. 
Failure to activate the UPR in cells under ER stress 
increases the risk of misfolded proteins accumulation, 
which can result in cell demise by activation of the intrinsic 
apoptotic pathway [13]. Myeloma cells produce large 
amounts of immunoglobulins, and are therefore expected 
to rely on constitutive UPR activation for cell survival. We 
confirmed that the IRE1α and PERK branches of the UPR 
are constitutively activated in these cells by monitoring 
IRE1α-induced XBP1 splicing (XBP1s), PERK-mediated 
phosphorylation of EIF2α and expression of CHOP and 
ATF4 (Figure 3A). Interestingly, we observed that T. 
brucei infection reduced constitutive activation of IRE1α 
and PERK (Figure 3A) which led to a general reduction 
in the amount of ubiquitinated proteins (Figure 3B) and 
a reduction in the amount of secreted M-protein at early 
time points (data not shown). To determine whether 
reduction of UPR activation induced by T. brucei could 
decrease MM viability, we performed a viability assay 
using purified MM cells and UPR inhibitors. We found 
that the combination of a PERK inhibitor and an IRE1α 
inhibitor for 24 hours gave a significant 40% reduction 
in MM viability, indicating that blocking the IRE1α 
and PERK branches of the UPR induces MM cell death 
(Figure 3C). To further confirm the functionality of the 
UPR inhibitors, we treated MM cells with the combination 
of inhibitors and analyzed activation of the IRE1α and 
PERK pathways by western blot. We found a reduction 
Figure 2: T. brucei mediated apoptosis of 5T33MM cells in vivo. 7 days after inoculation with 5T33MM cells, mice were divided into 
2 groups. One group was infected with T. brucei (n = 12, pooled to 4 samples), the other served as control (n = 3). Mice were sacrificed 
at day 20. 5T33MM cells were isolated from the bone marrow and purified to > 85% by depletion of CD11b+ cells with MACS sorting. 
Western blot analysis for pJNK, JNK, MCL-1, Bim EL/L/S, Bax, caspase-8, caspase-9, caspase-3 and PARP was performed. β-tubulin 
served as loading control. 
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in XBP1s, PERK and ATF4, which led to cleavage of 
caspase 3 and PARP (Figure 3D). Together, these results 
confirm that T. brucei infection reduces UPR activity and 
induces apoptosis of MM cells via the activation of the 
intrinsic caspase-9-dependent pathway, which ultimately 
leads to the cleavage of caspase-3 and PARP.
Effect of anti-IFNɣ treatment on Trypanosoma 
mediated apoptosis in vivo
T. brucei infection in 5T33MM mice was 
accompanied by an increase in IFNy levels in serum up 
to 25 ng/ml at day 20 (Figure 4A). Recently, our group 
has underscored the detrimental role of IFNɣ in mediating 
Figure 3: Effects of T. brucei on unfolded protein response pathways in 5T33MM cells. A.-B. 7 days after inoculation with 5T33MM 
cells, mice were divided into 2 groups. One group was infected with T. brucei (n = 12, pooled to 4 samples), the other served as control (n = 
3). Mice were sacrificed at day 20. 5T33MM cells were isolated from the bone marrow and purified to > 85% by depletion of CD11b+ cells 
with MACS sorting. Western blot analysis for PERK, ATF4, CHOP, IRE1, GRP-78, caspase-12, pEIF2A, EIF2A, XBP-1 was performed. 
β-tubulin served as loading control. B. From 2 samples of each group as depicted in A, further analysis was performed for ubiquinated 
proteins. β-tubulin served as loading control. C. Viability assay was performed for 24h with MM cells (purity > 90%) of 3 different mice. 
Cells were treated with a combination of a PERK and IRE1α inhibitor. *means p < 0.05. D. One experiment representing 3 is shown of 
MM cells (purity > 90%) which were treated with the combination of PERK and IRE1α inhibitors for 21 hours, followed by western blot 
analysis.
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the early loss of B cells by apoptosis during experimental 
African trypanosomiasis [14]. Therefore its potential 
role in the apoptosis of myeloma cells was investigated 
by treating T. brucei infected 5T33MM mice with anti-
IFNɣ antibodies. Since the immune system no longer 
cleared the infection, this resulted in higher parasitemia 
serum levels at day 13 and day 14 (Figure 4B). Anti-
IFNɣ treatment could only partially abrogate the effects 
on tumor load induced by T. brucei infection, namely an 
absolute increase in plasmacytosis of 10% (Figure 4C) and 
in M-spike of 3 g/l (Figure 4D). These data suggest that 
IFNɣ is involved but is not the only factor involved in T. 
brucei induced apoptosis of MM cells.
DISCUSSION
The detrimental role of pathogens on the 
development of various cancers has been widely 
documented in recent years [1, 2]. Only in a small number 
of cases microbes were shown to play a positive role on 
cancer outcome [15, 16]. MM is the 2nd most frequent 
hematological cancer, developing in the BM [5]. Although 
the survival of MM patients has been extended three-fold 
due to the introduction of new classes of anti-myeloma 
agents (e.g. proteasome inhibitors, immunomodulatory 
agents, histone deacetylase inhibitors and monoclonal 
antibodies,…) it still remains incurable for the majority of 
the patients [17-19]. So a better understanding of how MM 
cells proliferate, survive and resist therapy, is necessary to 
further develop new therapeutical agents. 
The 5T33MM model is an immune competent 
model that mimics the human disease characteristics 
very closely after inoculation of C57BL/KaLwRij mice 
with 5T33MM cells. Therefore the impact of a parasitic 
infection on the development of MM was tested using an 
in vivo African trypanosomiasis mouse model. Results 
obtained show that 5T33MM mice infected with T. brucei 
parasites displayed a substantial decrease in M-protein 
level as well as a significant drop in plasmacytosis. As 
a consequence trypanosomiasis plays a surprisingly 
Figure 4: Effect of anti-IFNy treatment on Trypanosoma mediated apoptosis in vivo. 7 days after inoculation with 5T33MMvv, 
mice were divided into 3 groups (n = 10/group): 2 groups were infected with T. brucei, one group served as control. Anti-IFNy treatment 
(300µg) was given to one of the T. brucei infected groups, 2-times a week intraperitoneally until the end of the experiment. All mice were 
sacrificed when first mice showed signs of morbidity. A. IFNy levels of T. brucei treated mice, measured in serum by ELISA. B. Blood 
parasitemia was counted at different time points. C.+D. Tumor load was evaluated by measuring plasmacytosis and M-protein levels. The 
bars represent mean +/- standard deviation (SD). *means p < 0,05, ** means p < 0,01, *** means p < 0,001, **** means p < 0,0001.
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positive role on the outcome of myeloma by considerably 
prolonging the survival of infected mice compared to 
PBS treated counterparts. This result is rather unique as 
parasitic infections mainly promote the development of 
cancer [20]. For example, different species of parasites 
living in the water in regions in Middle East, Asia and 
Africa and causing schistosomiases can promote bladder 
and colorectal cancers [21-23]. It is important to note that 
towards the end of the experiments, T. brucei infected 
C57BL/KaLwRij mice were no longer dying from 
unrestrained MM cell proliferation but from uncontrolled 
parasitemia due to their increased susceptibility to African 
trypanosome infection compared to resistant C57BL/6 
mice. Countering the infection by treating the T. brucei 
infected mice with Berenil resulted in reduced survival 
benefit indicating that the therapeutic effect depends on 
the presence of live parasite to dampen MM load. Hence, 
while exposure to trypanosome is obviously not a way 
forward in the search for a cure for MM, understanding the 
mechanisms that trypanosome exploits to alter the host’ B 
cell compartment might result in new insights that could 
fuel future anti-MM strategies.
Therefore, the mechanisms implicated in the 
suppression of MM cells following T. brucei infection 
were investigated. The analysis of multiple death-
associated pathways by Western Blot has shown an 
upregulation of cleaved caspase-3 and PARP on enriched 
BM-derived 5T33MM cells from T. brucei infected 
compared to uninfected mice, demonstrating a higher rate 
of apoptosis. Previous results by our group have already 
put forward that trypanosome infection resulted in the 
induction of apoptosis by different subsets of splenic B 
cells, such as transitional, marginal zone and follicular B 
cells [8, 9]. The effect of T. brucei infection on marginal 
zone B cells has been linked to the upregulation of pro-
apoptotic caspase-3 and the downregulation of anti-
apoptotic Bcl-2 marker [9]. In this study, a reduction in 
the levels of anti-apoptotic MCL-1 was observed. More 
recently, our group has demonstrated that trypanosome can 
hamper the development of arthritis in DBA/1 prone mice 
by specifically targeting antigen specific antibody levels 
[10]. By investigating the upstream pathway leading to 
apoptosis, we found that MM cells isolated from infected 
mice displayed induced cleavage of caspase-9, indicating 
activation of the intrinsic apoptotic pathway, in which 
mitochondria play a crucial role. This is not unique to 
trypanosoma infection since infection of MM cells with 
myxoma virus also induces activation of caspase-9. 
However, in that case, caspase-9 activation resulted from 
increased caspase-8 cleavage which is a member of the 
extrinsic apoptosis pathway [24]. Moreover, we and others 
have demonstrated that chemotherapeutic drugs used as 
treatment in the context of MM, act via the activation of 
the intrinsic mitochondrial apoptotic pathway, usually in 
a p53-dependent manner [25, 26]. In order to elucidate 
which pathways could lead to caspase-9 cleavage we 
analyzed the role of the UPR in MM apoptosis. Due to 
an overactive ER, MM cells are particularly sensitive to 
UPR inhibitors [27]. Here we confirmed that Trypanosome 
infection reduces the UPR in vivo and that the 5TMM 
cells are sensitive to the combined use of a PERK and 
IRE1α-XBP1 inhibitor, leading to enhanced caspase-3 
and PARP cleavage. This is particularly interesting since 
it has been demonstrated that activation of the UPR leads 
to drug resistance in MM cells [28]. By contrast, Leung-
Hagesteijn et al have shown that MM cells arrested at the 
plasmablast level have low XBP1s levels and are thereby 
less responsive to treatment with the proteasome inhibitor 
Bortezomib [29]. The relationship between different 
pathogens and the UPR has already been investigated in 
several models, however results have been conflicting. 
It is generally assumed that bacteria and viruses activate 
the UPR in host cells, however it has been shown that S. 
negevensis suppresses the UPR [30]. Furthermore we 
cannot exclude that the UPR reduction is a secondary 
event to the apoptosis induction. To our knowledge, our 
paper is the first to highlight a role of T. brucei in the 
modulation of the UPR within its host during infection.
Finally, the role of IFNɣ was investigated as a 
candidate factor that might be implicated in the triggering 
of the intrinsic apoptotic pathway in MM cells. Indeed, 
IFNɣ has been shown to play a major role in anti-tumor 
responses as well as in the control of trypanosomiasis. 
T. brucei infections promote the development of a Th1-
mediated immune response [31] and IFNɣ was recently 
implicated in the early B cell loss in a mouse model 
of African trypanosomiasis [14]. Our results showed 
that trypanosome infected mice treated with anti-IFNɣ 
blocking antibodies display statistically higher M-protein 
levels compared to untreated and infected mice, but no 
clear impact on BM plasmacytosis was seen. Since 
M-protein levels are the result of plasmacytosis both 
in BM and spleen, it is possible that IFNɣ mediated 
apoptosis of myeloma cells is more prominent in the 
spleen. However, both M-protein levels and plasmacytosis 
were still lower compared to uninfected 5T33MM mice. 
These data suggest that IFNɣ is partially implicated in the 
induced apoptosis of MM cells in T. brucei infected mice. 
Rakshit et al. suggested already a beneficial role for IFNɣ 
in MM. They demonstrated, using a solid Sp2/0 myeloma 
tumor that Mycobacterium indicus pranii induced anti-
myeloma T cell responses, which were highly reduced 
in Ifnɣ-/- mice. However, no significant differences 
were observed in tumor progression, again suggesting 
a role for other mechanisms contributing to anti-tumor 
responses [32]. Together, our results demonstrate that 
African trypanosome infections are able to shortcut the 
development of MM in a mouse model, by UPR pathway 
reduction and the induction of malignant plasma cell 
apoptosis via an intrinsic caspase-9-dependent pathway 
leading to increased cleavage of caspase-3 and PARP. 
A thorough understanding of the fine-tuned molecular 
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mechanisms implicated in this apoptotic process might 
potentially lead to the development of a new approach, 
strategy or therapy in order to fight MM. 
MATERIALS AND METHODS
Mice and cell lines
C57BL/KaLwRijHsd mice were purchased from 
Envigo (Horst, the Netherlands). Housing and maintenance 
was done according to the regulations approved by 
the Ethical Committee for Animal Experiments, Vrije 
Universiteit Brussel (CEP n° 14-281-12). The 5T33MM 
mouse model used in these studies, was previously 
described [11]. 5T33MM cells were isolated from the 
BM of diseased mice by crushing hind legs and vertebrae. 
After red blood cell lysis, purity of > 90% MM cells was 
confirmed on May-Grünwald Giemsa stained cytospins. 
For western blot analysis and viability assays, a further 
purification was performed by depleting CD11b+ cells 
(cells of myeloid lineage) with MACS sorting (Miltenyi 
Biotech, Leiden, The Netherlands).
Parasites and infection in mice
Clonal pleomorphic T. brucei AnTat 1.1E parasites 
were a kind gift from N. Van Meirvenne (Institute for 
Tropical Medicine, Belgium) and stored at −80°C. The 
pleomorphic AnTat1.1E (Eatro 1125 stock) T. brucei was 
used in this study as previously described [9]. Multi-wave 
parasitemia development characterizes this infection. 
Each wave represents a parasite population of different 
antigenic type. Each mouse was infected intraperitoneally 
with 5000 parasites 7 days after inoculation with 5T33MM 
cells. Where indicated, both infected and uninfected mice 
were treated i.p. with diminazene aceturate (Berenil 
or Veriben®, 40 mg/kg, CEVA SANTE ANIMALE, 
33501, France) in PBS. Depending on the set-up of the 
experiment, parasitemia was evaluated by counting the 
number of parasites in the blood (diluted 1/200 in PBS) 
with a counting chamber and light microscope.
ELISA
IFNɣ was quantified in the serum with an anti-IFNɣ 
ELISA (eBioscience, San Diego, CA, USA) following 
manufacturer’s instructions.
Viability assays
The effect of UPR inhibitors on MM viability was 
measured using a Cell Titer Glo Luminescent Viability 
assay (Promega, Madison, WI, USA). Briefly, purified 
MM cells were incubated with a PERK inhibitor (AMG 
PERK44, Tocris Bioscience, UK) and an IRE1 inhibitor 
(MKC8866). Inhibitors were used at 2.5µM and 10µM 
respectively, DMSO was used as control.
Western blot
Western blot was performed on purified 5T33MM 
cells as described previously [12] using the following 
antibodies: pJNK (Thr183/Tyr185), JNK, MCL-1, Bim 
(EL/L/S), Bax, Caspase-8, Caspase-9, Caspase-3, PARP, 
ATF4, Caspase-12, XBP1, CHOP and β-tubulin, all 
purchased from Cell Signaling Technology (Boston, MA, 
USA). PERK, IRE1, GRP-78, pEIF2A (Ser52) and EIF2A 
were purchased from Santa Cruz Biotechnology Inc. 
(Dallas, TX, USA) and Ubiquitin from Enzo Life Sciences 
(Farmingdale, NY, USA).
In vivo treatment with anti-IFNy
Mice were divided into 3 groups (n = 10/group): 2 
groups were infected with T. brucei, one group served as 
control. Anti-IFNɣ (clone XMG1.2) and its isotype control 
rat IgG1 (clone HRPN) were purchased from Bioxcell 
(West Lebanon, NH, USA) and dissolved in PBS (Lonza, 
Basel, Switzerland). Anti-IFNɣ treatment (300µg/mouse) 
was given intraperitoneally to one of the T. brucei infected 
groups starting 2 days post infection. Injections were 
repeated 2-times a week until the end of the experiment. 
All mice were sacrificed when first mice showed signs of 
morbidity or paralysis.
Statistics
Statistical analysis was done using GraphPad Prism 
6.0 software. All data represent the mean ± standard 
deviation (SD). The Mann-Whitney U test was used to 
analyze the data. Kaplan-Meier curves were analyzed by 
means of the Log-Rank method. p < 0,05 (*), p < 0,01 
(**), p < 0,001 (***), p < 0,0001 (****) were considered 
statistically significant.
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